Compazine and Xeljanz drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Compazine (prochlorperazine maleate) and Xeljanz (tofacitinib citrate). Common drug interactions include weight decreased among females and bronchitis among males.

The phase IV clinical study analyzes what interactions people have when they take Compazine and Xeljanz. It is created by eHealthMe based on reports of 30 people who take the same drugs from the FDA, and is updated regularly.

What is Compazine?

Compazine has active ingredients of prochlorperazine maleate. It is often used in indigestion. eHealthMe is studying from 13,646 Compazine users. Check the latest studies of Compazine.

What is Xeljanz?

Xeljanz has active ingredients of tofacitinib citrate. It is often used in rheumatoid arthritis. eHealthMe is studying from 239,081 Xeljanz users. Check the latest studies of Xeljanz.



On Jul, 19, 2026

30 people who take Compazine and Xeljanz together, and have interactions are studied.

Compazine and Xeljanz drug interactions.

What are the common drug interactions of Compazine and Xeljanz, by gender? *:

female:

  1. Weight decreased
  2. Carpal tunnel syndrome (nerve compression at wrist results numbness weakness, pain , swelling)
  3. Drug hypersensitivity
  4. Alopecia (absence of hair from areas of the body)
  5. Anxiety
  6. Drug intolerance (drug sensitivity)
  7. Feeling jittery
  8. Increased appetite
  9. Intervertebral disc degeneration (spinal disc degeneration)
  10. Neuropathy peripheral (surface nerve damage)

male:

  1. Bronchitis (inflammation of the mucous membrane in the bronchial tubes)
  2. Contusion (a type of hematoma of tissue in which capillaries)
  3. Infusion site extravasation (flow of (blood or lymph) from infusion site)
  4. Poor venous access
  5. Fall
  6. Gastrointestinal disorder (functional problems of gastrointestinal tract)
  7. Infusion related reaction
  8. Migraine (headache)
  9. Skin irritation
  10. Surgery

What are the common drug interactions of Compazine and Xeljanz, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

  1. Acne (skin problems that cause pimples)
  2. Drug hypersensitivity
  3. Influenza like illness
  4. Crying
  5. Depressed mood
  6. Fatigue (feeling of tiredness)
  7. Fear
  8. Feelings of worthlessness
  9. Malaise (a feeling of general discomfort or uneasiness)
  10. Mood altered (changes in mood)

50-59:

  1. Dysphagia (a condition in which swallowing is difficult or painful)
  2. Eyelid ptosis (falling of the upper or lower eyelid)
  3. Food allergy
  4. Gastrointestinal haemorrhage (bleeding gastrointestinal tract)
  5. Milk allergy
  6. Muscular weakness (muscle weakness)
  7. Mycotic allergy (fungal allergy)
  8. Respiratory failure (inadequate gas exchange by the respiratory system)
  9. Blood pressure increased
  10. Bone pain

60+:

  1. Carpal tunnel syndrome (nerve compression at wrist results numbness weakness, pain , swelling)
  2. Weight decreased
  3. Pelvic fracture
  4. Peripheral nerve lesion
  5. Spinal column stenosis (narrowing of spinal column)
  6. Urinary tract infection
  7. Sleep disorder
  8. Arthritis (form of joint disorder that involves inflammation of one or more joints)
  9. Bronchitis (inflammation of the mucous membrane in the bronchial tubes)
  10. Infusion related reaction

What are the existing conditions these people have? *

  1. Weight Decreased: 6 people, 20.00%
  2. Pain In Jaw: 6 people, 20.00%
  3. Crohn's Disease (a condition that causes inflammation of the gastrointestinal tract): 5 people, 16.67%
  4. Short-Bowel Syndrome (a condition in which the body cannot absorb enough fluids and nutrients because part of the small intestine is missing): 4 people, 13.33%
  5. Pain: 4 people, 13.33%
  6. Nausea (feeling of having an urge to vomit): 3 people, 10.00%
  7. Chronic Inflammatory Demyelinating Polyradiculoneuropathy (long lasting infection of nerves outside brain and spinal cord): 3 people, 10.00%
  8. Stress And Anxiety: 3 people, 10.00%
  9. Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 2 people, 6.67%
  10. Asthma: 2 people, 6.67%

* Approximation only. Some reports may have incomplete information.

Do you take Compazine and Xeljanz?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Compazine and Xeljanz:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Compazine:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Xeljanz:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Compazine and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Xeljanz and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on prochlorperazine maleate and tofacitinib citrate (the active ingredients of Compazine and Xeljanz, respectively), and Compazine and Xeljanz (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: